Neoadjuvant Trebananib Plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Kathy S. Albain , Christina Yau , Emanuel F. Petricoin , Denise M. Wolf , Julie E. Lang , A. Jo Chien , Tufia Haddad , Andres Forero-Torres , Anne M. Wallace , Henry Kaplan , Lajos Pusztai , David Euhus , Rita Nanda , Anthony D. Elias , Amy S. Clark , Constantine Godellas , Judy C. Boughey , Claudine Isaacs , Debu Tripathy , Janice Lu , Rachel L. Yung , Rosa I. Gallagher , Julia D. Wulfkuhle , Lamorna Brown-Swigart , Gregor Krings , Yunn Yi Chen , David A. Potter , Erica Stringer-Reasor , Sarah Blair , Smita M. Asare , Amy Wilson , Gillian L. Hirst , Ruby Singhrao , Meredith Buxton , Julia L. Clennell , Ashish Sanil , Scott Berry , Adam L. Asare , Jeffrey B. Matthews , Angela M. Demichele , Nola M. Hylton , Michelle Melisko , Jane Perlmutter , Hope S. Rugo , W. Fraser Symmans , Laura J. van't Veer , Douglas Yee , Donald A. Berry , Laura J. Esserman CLINICAL CANCER RESEARCH（2024）
AI 理解论文
溯源树
样例
